Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announced today that its clinical facility in Mexico City has begun recruiting patients for Group Two of its ongoing human clinical study of the Ocumetics Lens, a next-generation accommodating intraocular lens designed to provide clear vision at all distances without glasses or contact lenses.
The initiation of Group Two marks a significant progression in the company's clinical development. Unlike the initial Group One study, which focused solely on safety, Group Two will evaluate the lens for safety plus near- and distance-vision performance. Patients enrolled in this phase will receive the latest-generation Ocumetics Lens implanted with an enhanced delivery system, reflecting the company's continued technological advancements.
Dr. Dean Burns, President and CEO of Ocumetics, expressed enthusiasm about reaching this milestone. "We are extremely excited to begin the process of moving into our larger Group Two study. Commencement of this study represents another important milestone in the continued clinical development of the Ocumetics Lens. Recruiting will be completed soon and we will schedule surgical dates shortly thereafter," he said.
The Group One clinical outcomes, which met and exceeded expectations regarding safety, performance, and handling, have provided valuable insights. Patients from that group are now reaching their 12-month follow-up visits, an important milestone that will supply longer-term clinical data. This data will be crucial in demonstrating the durability and sustained efficacy of the lens.
The Ocumetics Lens represents a paradigm shift in vision correction. Traditional intraocular lenses used in cataract surgery are monofocal, providing vision at a single distance, or multifocal, which can compromise contrast sensitivity. The Ocumetics Lens, however, mimics the eye's natural accommodative ability by utilizing the eye's own muscles to shift focus between distances. This could potentially eliminate the need for corrective lenses entirely, offering a life-changing solution for millions of people.
The company's ongoing clinical program is a critical step toward regulatory approval and commercialization. By initiating Group Two, Ocumetics is not only advancing its clinical evidence but also demonstrating its commitment to developing a truly differentiated product. The enhanced delivery system included in this phase is designed to improve surgical outcomes, ensuring precise implantation and optimal positioning.
"We are particularly excited to reach the 12-month milestone for our Group One patients, which will provide an important body of longer-term clinical data as we continue to advance the Ocumetics Lens," Burns added. "At the same time, the Group Two study represents an important step forward as we introduce our next-generation Ocumetics Lens together with our next-generation lens delivery system. This combination represents the continued evolution of our technology and our commitment to developing a truly differentiated solution for patients seeking improved vision across a broader range of distances."
The recruitment process is underway in Mexico City, with surgeries targeted for fall 2026. The company expects to complete enrollment soon and schedule surgical dates shortly thereafter. Positive results from Group Two could pave the way for larger pivotal trials and eventual market entry, potentially disrupting the ophthalmic industry.
The implications of this announcement are substantial. For patients, the possibility of never needing glasses or contacts again is a compelling value proposition. For the ophthalmic community, a successful accommodating IOL could set a new standard of care. For investors, this progress indicates that Ocumetics is on track with its clinical roadmap, mitigating some of the risks associated with early-stage medical device development.
As the study progresses, all eyes will be on the outcomes. With the combination of a next-generation lens and delivery system, Ocumetics is positioning itself at the forefront of vision correction technology. The company's commitment to rigorous clinical evaluation underscores its dedication to safety and efficacy, which are paramount in medical device development.
For more information about Ocumetics and its technology, interested parties are encouraged to follow the company's ongoing announcements. The initiation of Group Two is a positive indicator of the potential of this technology to transform lives.
